{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2020"],"data_sharing_plan":["IPD Sharing (as of October 2023): No\nDescription: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche’s criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche’s Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)."],"condition":["Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","Colorectal Cancer","Advanced Solid Tumors","Colorectal Neoplasms"],"disease":["Colorectal Cancer","Advanced Solid Tumors","Non-small Cell Lung Cancer","Colorectal Neoplasms","Carcinoma, Non-small-cell Lung"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2343954"],"location":["Hungary","United States","United Kingdom","Kenya","Switzerland","Russia","Spain","New Zealand","Canada","South Korea","Netherlands","Belgium","Norway","Brazil","Poland","Italy","Israel","Australia"],"study_start_month":["7"],"keyword":["Erlotinib Hydrochloride","SHP2","Erlotinib","Metastatic Solid Tumor","GDC-6036","GDC-1971","KRAS G12C","Cetuximab","Inavolisib","Atezolizumab","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation","description":"This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.","dates":{"creation":"2020-07-15"},"accession":"2343954","cross_references":{"ClinicalTrials___gov":["NCT04449874"],"EU Clinical Trials Register":["2020-000084-22","2023-506311-18"]}}